72 completed, 31 unknown, 16 recruiting, 14 terminated. 42 Not applicable, 32 Phase 2, 18 Phase 3, 16 Phase 1, 7 Phase 4.
Follow this condition Literature Review of Drug Hypersensitivity trials Research Report on Drug Hypersensitivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis Site specific standard of care comparison - Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis | Withdrawn | Massachusetts General Hospital | 2030-01-01 | 2026-01-16 | ||
| Interest of a Targeted Therapy for the Treatment of a Severe Form of Hypersensitivity to Drug (DRESS Syndrome) Benralizumab 30 MG/ML [Fasenra], Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride - DRESS Syndrome | Phase 2 | Not yet recruiting | University Hospital, Lille | 96 | 2027-01-06 | 2026-05-15 |
| Subconjunctival Humira for Boston Keratoprosthesis Adalimumab Injection - Penetrating Keratoplasty, Multiple Graft Failure | Phase 1 | Not yet recruiting | Massachusetts Eye and Ear Infirmary | 8 | 2026-10-01 | 2026-08-31 |
| Traditional Chinese Medicine Treatment for Capecitabine-Related Hand-Foot Syndrome Twelve-Ingredient Prepared Sichuan Aconite Hand and Foot Bath, Standard Basic Nursing Interventions - Palmar and Plantar Erythema, Numbness of the Four Limbs | Early Phase 1 | Not yet recruiting | Emeishan Hospital of Traditional Chinese Medicine | 7 | 2026-10-01 | 2026-10-20 |
| Post-market Safety Study of LUMISIGHT Hypersensitivity Reactions | Recruiting | Lumicell, Inc. | 1500 | 2026-09-30 | 2026-10-14 | |
| TAR-0520 Gel in Hand and Foot Syndrome TAR-0520 gel - Hand and Foot Syndrome | Phase 2 | Not yet recruiting | Tarian Pharma | 25 | 2026-03-01 | 2026-03-09 |
| Traditional Chinese Medicine Hand-Foot Soak for Chemotherapy-Induced Peripheral Neuropathy and Hand-Foot Syndrome Traditional Chinese Medicine - Patients With Solid Tumors | Not yet recruiting | Peking University Third Hospital | 300 | 2026-02-01 | 2026-01-29 | |
| Establishment of a Registry for Immediate Drug Allergy Drug Hypersensitivity | Not yet recruiting | Yonsei University | 200 | 2026-02-01 | 2026-02-05 | |
| HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness HLA-B*58:01 Genotyping, Allopurinol Tablet, Febuxostat - Gout Initiating Urate-loweringUrate-lowering Therapy, Gout Arthritis | Phase 4 | Not yet recruiting | Haiphong University of Medicine and Pharmacy | 228 | 2026-01-20 | 2026-01-27 |
| New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies. DARATUMUMAB (DARZALEX®) - Toxic Epidermal Necrolysis, Immunotherapy | Phase 1 / Phase 2 | Not yet recruiting | Hospices Civils de Lyon | 9 | 2025-10-29 | 2025-08-07 |
| Long-term Effect of Dupilumab in N-ERD Observational follow-up of standard Dupilumab treatment - NSAID-Induced Asthma, NSAIDs Hypersensitivity | Completed | Medical University of Vienna | 15 | 2025-09-01 | 2026-10-07 | |
| Provocation After Nurse-Directed Assessment (PANDA) Study Nurse-led penicillin allergy delabelling service, Allergist-led penicillin allergy delabelling service - Drug Allergy, Penicillin Allergy | Recruiting | The University of Hong Kong | 440 | 2025-09-01 | 2026-04-29 | |
| Turkish Version of the Parent-Reported Drug Hypersensitivity Quality of Life Questionnaire Turkish Version of the P-DrHy-Q - Drug Hypersensitivity, Quality of Life (QOL) | Completed | Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization | 74 | 2025-08-01 | 2025-12-08 | |
| In Search of the Correct Diagnosis of Beta-lactam Allergy: From the Validation of a Risk Stratification Tool to Accurate Endotyping BL-Predicter - Drug Allergy | Not applicable | Not yet recruiting | Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud | 332 | 2025-07-01 | 2025-06-08 |
| Autologous Serum Obtained by a Closed-Circuit Collection Device Autologous Serum 20% - GVHD, Meibomian Gland Dysfunction (Disorder) | Phase 2 | Active not recruiting | GIANCARLO FATOBENE | 16 | 2025-06-20 | 2026-10-21 |
| Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer Proactive immune tolerance induction, Standard Treatment, Paclitaxel and carboplatin - Ovarian Cancer, Endometrial Cancer | Not applicable | Recruiting | Seoul National University Hospital | 1000 | 2025-05-21 | 2026-10-07 |
| Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing, Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge, Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge - Drug Allergy, Cephalosporin Allergy | Phase 2 | Recruiting | Massachusetts General Hospital | 300 | 2025-05-05 | 2026-09-04 |
| Support Tool for Antibiotic Allergy deLabeling EPR search - Antibiotic Allergy | Not applicable | Recruiting | Universitaire Ziekenhuizen KU Leuven | 3000 | 2025-03-10 | 2025-12-16 |
| Impact of CES1 Genotype on Capecitabine Exposure in Cancer Patients Blood sampling for pharmacokinetics - Solid Cancer, Gastric (Cardia, Body) Cancer | Recruiting | Erasmus Medical Center | 66 | 2025-02-18 | 2025-08-11 | |
| Teicoplanin Allergy Testing Using Autologous Serum (TATAS) Teicoplanin Allergy Testing using autologous serum - Drug Allergy | Not applicable | Recruiting | University Hospital Southampton NHS Foundation Trust | 20 | 2025-01-08 | 2025-01-31 |
Showing 20 of 154. Sign in to see all of them.
Hand-Foot Syndrome (42) · Stevens-Johnson Syndrome (40) · Asthma, Aspirin-Induced (12) · Hypersensitivity (12) · Breast Neoplasms (10) · Drug-Related Side Effects and Adverse Reactions (8) · Anaphylaxis (7) · Drug Hypersensitivity Syndrome (7) · Colorectal Neoplasms (6) · Dry Eye Syndromes (5) · Neoplasms (5) · Pemphigoid, Benign Mucous Membrane (5) · Asthma (4) · Nasal Polyps (4)
Chemically-Induced Disorders (154) · Drug-Related Side Effects and Adverse Reactions (146) · Skin and Connective Tissue Diseases (93) · Skin Diseases (92) · Dermatitis (91) · Drug Eruptions (88) · Immune System Diseases (74) · Hypersensitivity (62) · Hypersensitivity, Delayed (47) · Erythema (41) · Mouth Diseases (41) · Skin Diseases, Vesiculobullous (41) · Stomatognathic Diseases (41) · Stomatitis (40)
Pyridoxine (4) · Aspirin (3) · Blood Specimen Collection (3) · Infliximab (3) · ifetroban (3) · Allopurinol (2) · Amoxicillin (2) · Capecitabine (2) · Celecoxib (2) · Chondroitinases and Chondroitin Lyases (2) · Clobetasol (2) · Cyclosporine (2) · Etanercept (2) · Filgrastim (2) · Prednisone (2)
University Hospital, Montpellier (8) · Chulalongkorn University (5) · Assistance Publique - Hôpitaux de Paris (4) · Seoul National University Hospital (4) · Brigham and Women's Hospital (3) · Mahidol University (3) · Massachusetts Eye and Ear Infirmary (3) · Massachusetts General Hospital (3) · Bausch & Lomb Incorporated (2) · Chang Gung Memorial Hospital (2) · Cumberland Pharmaceuticals (2) · Cyprus University of Technology (2) · Hospices Civils de Lyon (2) · Montefiore Medical Center (2) · Peking University Third Hospital (2)
United States (37) · France (23) · China (9) · Thailand (8) · Belgium (7) · Spain (6) · Brazil (4) · Germany (4) · South Korea (4) · Turkey (Türkiye) (4) · Canada (3) · Egypt (3) · Switzerland (3) · Taiwan (3) · United Kingdom (3)
Jettanong Klaewsongkram, MD (4) · Andrei Hancharou, Dr (2) · Elliot Israel, MD (2) · James Chodosh, MD, MPH (2) · Lisa R Grillone, PhD (2) · Pinnita Prabhasawat, MD (2) · Rik Schrijvers, MD, PhD (2) · Tanya M Laidlaw, MD (2) · Aaron Sulkes, MD (1) · Alexander Navarini, MD (1) · Anca Chiriac, MD,PhD (1) · Andrea Fong, MD, FRCPC (1) · Andrew White, MD (1) · Antonina Osipova, Dr (1)
PMID 28715540, PMID 12558848, PMID 12746667, PMID 12907084, PMID 15161841, PMID 15287367, PMID 17885735, PMID 17919775, PMID 20625131, PMID 21940785, PMID 22578340, PMID 22722755, PMID 23569753, PMID 24021017, PMID 24188976, PMID 24565482, PMID 24656636, PMID 24795111, PMID 24928706, PMID 25293768, PMID 25592341, PMID 26110680, PMID 26297574, PMID 27043788, PMID 27106261, PMID 28341170, PMID 28370003, PMID 28383633, PMID 28476287, PMID 28483317, PMID 28564564, PMID 28587598, PMID 29037870, PMID 29095653, PMID 29400697, PMID 29425903, PMID 29478292, PMID 29678929, PMID 29756474, PMID 29800753, PMID 29800754, PMID 29802906, PMID 29803713, PMID 29883754, PMID 30204536, PMID 30346532, PMID 30539829, PMID 30782413, PMID 30903298, PMID 32597691
2025 (2), U01AI184071 (1), U19AI095219 (1)